Recommended Global Gastroenterology Webinars & Conferences
Europe & UK
Asia Pacific & Middle East
Canada
Liver Diseases 2027
About the Conference
18th International Conference on Liver Diseases & Hepatology
April 22–23, 2027 | Paris, France
Welcome
The 18th International Conference on Liver Diseases & Hepatology invites hepatologists, gastroenterologists, clinicians, surgeons, researchers, academicians, healthcare professionals, pharmaceutical experts, and industry leaders from around the world to gather in Paris, France, on April 22–23, 2027.
The conference serves as a premier international platform for presenting cutting-edge research, sharing clinical experiences, discussing emerging technologies, and fostering collaborations that improve the prevention, diagnosis, and treatment of liver diseases. Participants will gain valuable insights into the latest scientific discoveries, innovative therapeutic approaches, artificial intelligence in hepatology, liver transplantation, metabolic liver disorders, viral hepatitis, liver cancer, and precision medicine.
The scientific program will feature keynote lectures, plenary sessions, oral and poster presentations, workshops, panel discussions, and networking opportunities designed to encourage interdisciplinary collaboration and accelerate advances in hepatology. The conference aims to bring together more than 300 participants from academia, healthcare institutions, research organizations, and industry worldwide.
Why Attend?
- Learn from internationally renowned experts in hepatology and gastroenterology.
- Discover the latest breakthroughs in liver disease diagnosis and treatment.
- Explore innovations in AI, digital health, and precision medicine.
- Present your research to an international scientific audience.
- Build collaborations with researchers, clinicians, and industry professionals.
- Gain exposure to the latest pharmaceutical products, medical technologies, and clinical trials.
- Enhance professional development through scientific discussions and networking.
- Explore publication opportunities for accepted abstracts.
Who Should Attend?
- Hepatologists
- Gastroenterologists
- Liver Transplant Surgeons
- Internal Medicine Physicians
- Oncologists
- Clinical Researchers
- Scientists
- Medical Faculty
- Healthcare Professionals
- Pharmacologists
- Biotechnology Researchers
- Medical Students
- Residents & Fellows
- Pharmaceutical and Biotechnology Companies
- Public Health Professionals
Call for Abstracts
Researchers, clinicians, academicians, healthcare professionals, and students are invited to submit original scientific abstracts showcasing innovative research, clinical studies, systematic reviews, and case reports related to liver diseases and hepatology.
Accepted abstracts will be evaluated by the Scientific Committee and presented during the conference. Selected abstracts may also be considered for publication in associated scientific journals, subject to editorial review.
Conference Highlights
- International Keynote Speakers
- Plenary Sessions
- Scientific Oral Presentations
- Poster & E-Poster Sessions
- Young Research Forum
- Panel Discussions
- Workshops
- Industry Exhibitions
- B2B Networking Meetings
- Certificate of Participation
- Publication Opportunities
- Awards for Best Oral & Poster Presentations
Join Us in Paris
Be part of the 18th International Conference on Liver Diseases & Hepatology to exchange knowledge, discover pioneering research, and contribute to shaping the future of liver disease diagnosis, treatment, and patient care. Join leading experts from across the globe in Paris, France, on April 22–23, 2027, for two inspiring days of scientific excellence, collaboration, and innovation.
Call for Abstracts
Researchers, clinicians, academicians, healthcare professionals, and students are invited to submit original scientific abstracts showcasing innovative research, clinical studies, systematic reviews, and case reports related to liver diseases and hepatology.
Abstract Categories
- Keynote Presentations
- Oral Presentations
- Poster Presentations
- Young Research Forum
- E-Poster Presentations
- Workshops
- Case Reports
Accepted abstracts will be evaluated by the Scientific Committee and presented during the conference. Selected abstracts may also be considered for publication in associated scientific journals, subject to editorial review.
Sessions and Tracks
Liver Diseases & Hepatology
Liver Diseases & Hepatology focuses on the prevention, diagnosis, and management of acute and chronic liver disorders that significantly impact global health. This track covers a broad spectrum of liver diseases, including viral hepatitis, fatty liver disease, alcoholic liver disease, cirrhosis, liver fibrosis, autoimmune liver disorders, metabolic liver diseases, and hepatocellular carcinoma. Discussions will highlight advances in diagnostic imaging, molecular biomarkers, precision medicine, antiviral therapies, regenerative medicine, and liver transplantation. Experts will share the latest clinical research, innovative therapeutic approaches, and multidisciplinary strategies to improve liver health and patient outcomes.
Related Topics:
Liver Diseases | Hepatology | Liver Research | Chronic Liver Disease | Clinical Hepatology | Liver Health
Viral Hepatitis (HBV, HCV, HDV & HEV)
Viral Hepatitis remains one of the leading causes of chronic liver disease and liver-related mortality worldwide. This session explores the epidemiology, pathogenesis, diagnosis, prevention, and treatment of hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and hepatitis E (HEV). Topics include antiviral therapies, vaccination strategies, drug resistance, liver fibrosis progression, hepatocellular carcinoma prevention, and global hepatitis elimination initiatives. Participants will discuss emerging biomarkers, novel therapeutics, and public health approaches aimed at reducing the burden of viral hepatitis.
Related Topics:
Viral Hepatitis | Hepatitis B (HBV) | Hepatitis C (HCV) | Hepatitis D (HDV) | Hepatitis E (HEV) | Antiviral Therapy
Fatty Liver Disease (MASLD/NAFLD & NASH)
Fatty Liver Disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), and Non-Alcoholic Steatohepatitis (NASH), has become one of the fastest-growing causes of chronic liver disease worldwide. This track focuses on disease mechanisms, metabolic risk factors, obesity, diabetes, diagnostic biomarkers, imaging techniques, lifestyle interventions, pharmacological therapies, and emerging treatments. Discussions will emphasize early detection, prevention of disease progression, and precision medicine approaches to improve patient care and long-term liver health.
Related Topics:
Fatty Liver Disease | MASLD | NAFLD | NASH | Metabolic Liver Disease | Liver Metabolism
Alcohol-Associated Liver Disease
Alcohol-Associated Liver Disease (ALD) encompasses a spectrum of liver conditions ranging from fatty liver and alcoholic hepatitis to advanced fibrosis and cirrhosis. This session explores the pathophysiology of alcohol-induced liver injury, genetic susceptibility, inflammatory mechanisms, diagnostic advances, nutritional management, pharmacological treatments, and liver transplantation. Experts will discuss strategies for alcohol cessation, multidisciplinary patient care, and innovative therapeutic interventions that reduce disease progression and improve survival.
Related Topics:
Alcohol-Associated Liver Disease | Alcoholic Hepatitis | Alcoholic Liver Disease | Liver Injury | Hepatology Research | Liver Care
Liver Fibrosis and Cirrhosis
Liver Fibrosis and Cirrhosis represent progressive stages of chronic liver disease characterized by excessive scar tissue formation and impaired liver function. This track examines the molecular mechanisms of fibrosis, diagnostic biomarkers, non-invasive imaging techniques, portal hypertension, complications of cirrhosis, and emerging antifibrotic therapies. Discussions will focus on early diagnosis, disease monitoring, regenerative medicine, liver transplantation, and innovative treatment strategies designed to slow disease progression and improve clinical outcomes.
Related Topics:
Liver Fibrosis | Cirrhosis | Chronic Liver Disease | Portal Hypertension | Antifibrotic Therapy | Liver Regeneration
Autoimmune Liver Diseases
Autoimmune Liver Diseases comprise a group of chronic immune-mediated disorders in which the body's immune system mistakenly attacks liver tissue, leading to inflammation and progressive liver damage. This track focuses on autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlap syndromes. Discussions will cover disease pathogenesis, genetic susceptibility, diagnostic biomarkers, immunological mechanisms, advanced imaging, immunosuppressive therapies, biologic treatments, and long-term disease management. Experts will also explore emerging therapeutic strategies and precision medicine approaches aimed at improving patient outcomes.
Related Topics:
Autoimmune Liver Diseases | Autoimmune Hepatitis | Primary Biliary Cholangitis | Primary Sclerosing Cholangitis | Immunology in Hepatology | Chronic Liver Disease
Pediatric Liver Disorders
Pediatric Liver Disorders encompass a wide range of congenital, genetic, infectious, metabolic, and autoimmune liver diseases affecting infants, children, and adolescents. This session explores biliary atresia, neonatal cholestasis, pediatric fatty liver disease, inherited metabolic disorders, viral hepatitis, and pediatric liver transplantation. Discussions will focus on early diagnosis, advanced imaging, nutritional support, multidisciplinary care, and emerging therapies that improve survival and long-term quality of life in pediatric patients.
Related Topics:
Pediatric Liver Disorders | Pediatric Hepatology | Biliary Atresia | Neonatal Liver Disease | Pediatric Liver Transplantation | Child Liver Health
Cholestatic Liver Diseases
Cholestatic Liver Diseases are characterized by impaired bile formation or bile flow, leading to progressive liver injury and complications if left untreated. This track focuses on conditions such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), inherited cholestatic disorders, and drug-induced cholestasis. Topics include disease mechanisms, diagnostic biomarkers, advanced imaging, endoscopic interventions, medical therapies, and liver transplantation. Participants will explore novel treatment strategies and clinical research aimed at improving patient care and disease outcomes.
Related Topics:
Cholestatic Liver Diseases | Primary Biliary Cholangitis | Primary Sclerosing Cholangitis | Bile Duct Disorders | Cholestasis | Hepatobiliary Diseases
Liver Transplantation
Liver Transplantation remains the gold standard treatment for patients with end-stage liver disease, acute liver failure, and selected liver cancers. This session highlights recent advances in donor selection, organ preservation, living donor liver transplantation, transplant immunology, immunosuppressive therapies, postoperative management, and long-term graft survival. Experts will discuss innovations in surgical techniques, ethical considerations, transplant outcomes, and emerging regenerative medicine approaches that continue to improve the success of liver transplantation.
Related Topics:
Liver Transplantation | Organ Transplantation | Living Donor Liver Transplant | Transplant Immunology | Liver Failure | Hepatic Surgery
Hepatic Surgery and Interventional Hepatology
Hepatic Surgery and Interventional Hepatology focus on advanced surgical and minimally invasive procedures for the diagnosis and treatment of liver diseases. This track covers liver resection, ablation techniques, transarterial chemoembolization (TACE), radioembolization, portal vein embolization, biliary interventions, and image-guided therapies for liver tumors and chronic liver disorders. Discussions will emphasize multidisciplinary management, perioperative care, technological innovations, and improved clinical outcomes through modern hepatobiliary interventions.
Related Topics:
Hepatic Surgery | Interventional Hepatology | Liver Resection | TACE | Radioembolization | Image-Guided Liver Therapy
Precision Medicine in Hepatology
Precision Medicine in Hepatology is revolutionizing liver disease management by integrating genomics, molecular diagnostics, biomarkers, artificial intelligence, and individualized therapeutic strategies. This session explores personalized treatment approaches for viral hepatitis, fatty liver disease, liver cancer, autoimmune liver diseases, and rare genetic liver disorders. Topics include pharmacogenomics, predictive biomarkers, multi-omics technologies, targeted therapies, and AI-driven clinical decision support. Participants will examine how precision medicine is enhancing early diagnosis, optimizing treatment selection, and improving long-term patient outcomes.
Related Topics:
Precision Medicine in Hepatology | Genomic Medicine | Personalized Liver Care | Biomarker Research | Pharmacogenomics | AI in Hepatology
Artificial Intelligence & Digital Health in Liver Care
Artificial Intelligence (AI) and Digital Health are transforming the diagnosis, monitoring, and management of liver diseases through advanced analytics, predictive modeling, and personalized patient care. This track explores AI-assisted imaging, machine learning algorithms, digital biomarkers, telehepatology, remote patient monitoring, and clinical decision-support systems. Discussions will focus on improving early detection of liver diseases, optimizing treatment strategies, enhancing patient engagement, and integrating digital technologies into routine hepatology practice. Experts will also address ethical considerations, data privacy, and the future of AI-driven liver healthcare.
Related Topics:
Artificial Intelligence in Hepatology | Digital Health | Telehepatology | Machine Learning in Liver Care | Digital Biomarkers | Healthcare Innovation
Liver Imaging and Diagnostic Technologies
Liver Imaging and Diagnostic Technologies play a critical role in the early detection, staging, and monitoring of liver diseases. This session highlights recent advances in ultrasound, elastography, computed tomography (CT), magnetic resonance imaging (MRI), contrast-enhanced imaging, liver biopsy techniques, and molecular diagnostics. Participants will explore innovative imaging modalities, non-invasive fibrosis assessment, AI-assisted diagnostics, and biomarker research that improve diagnostic accuracy and guide personalized treatment strategies in hepatology.
Related Topics:
Liver Imaging | Diagnostic Technologies | Elastography | MRI in Hepatology | CT Imaging | Liver Biomarkers
Clinical Hepatology and Case Studies
Clinical Hepatology and Case Studies provide a platform for discussing real-world clinical experiences, complex liver disease management, and evidence-based treatment strategies. This track features challenging clinical cases involving viral hepatitis, fatty liver disease, cirrhosis, autoimmune liver diseases, liver transplantation, and hepatocellular carcinoma. Experts will present diagnostic dilemmas, multidisciplinary approaches, treatment outcomes, and emerging clinical guidelines that enhance decision-making and improve patient care.
Related Topics:
Clinical Hepatology | Case Studies in Hepatology | Liver Disease Management | Clinical Research | Evidence-Based Hepatology | Patient Care
Portal Hypertension
Portal Hypertension is a serious complication of chronic liver disease and cirrhosis, resulting from increased pressure within the portal venous system. This session explores the pathophysiology, diagnosis, hemodynamic assessment, and management of portal hypertension and its complications, including variceal bleeding, ascites, hepatic encephalopathy, and hypersplenism. Discussions will cover pharmacological therapies, endoscopic interventions, transjugular intrahepatic portosystemic shunt (TIPS), surgical options, and advances in non-invasive monitoring to improve patient outcomes.
Related Topics:
Portal Hypertension | Esophageal Varices | Ascites | Hepatic Encephalopathy | TIPS Procedure | Cirrhosis Complications
Acute and Chronic Liver Failure
Acute and Chronic Liver Failure are life-threatening conditions associated with significant morbidity and mortality, requiring timely diagnosis and specialized multidisciplinary care. This track focuses on the causes, pathophysiology, clinical presentation, and management of acute liver failure, acute-on-chronic liver failure (ACLF), and end-stage chronic liver disease. Topics include organ support systems, intensive care management, liver transplantation, regenerative therapies, prognostic scoring systems, and emerging treatment strategies aimed at improving survival and long-term patient outcomes.
Related Topics:
Acute Liver Failure | Chronic Liver Failure | Acute-on-Chronic Liver Failure (ACLF) | Critical Care Hepatology | Liver Transplantation | Intensive Liver Care
Hepatic Encephalopathy
Hepatic Encephalopathy is a serious neurological complication of advanced liver disease caused by the accumulation of toxins, particularly ammonia, due to impaired liver function. This track explores the pathophysiology, clinical manifestations, diagnostic approaches, neurocognitive assessment, and evidence-based management of hepatic encephalopathy. Discussions will cover emerging biomarkers, gut microbiome modulation, nutritional interventions, pharmacological therapies, prevention strategies, and multidisciplinary approaches aimed at improving neurological function and patient quality of life.
Related Topics:
Hepatic Encephalopathy | Neurological Complications of Liver Disease | Ammonia Metabolism | Cirrhosis Complications | Gut-Liver Axis | Neurohepatology
Drug-Induced Liver Injury
Drug-Induced Liver Injury (DILI) is a leading cause of acute liver failure and an important challenge in clinical hepatology. This session examines the mechanisms of hepatotoxicity, risk factors, diagnostic criteria, causative medications, herbal and dietary supplements, pharmacovigilance, and treatment strategies. Experts will discuss biomarkers, liver safety assessment, regulatory perspectives, and emerging research aimed at improving early diagnosis, prevention, and management of drug-related liver injury.
Related Topics:
Drug-Induced Liver Injury | Hepatotoxicity | Liver Safety | Clinical Pharmacology | Drug Safety Research | Pharmacovigilance
Metabolic and Genetic Liver Disorders
Metabolic and Genetic Liver Disorders include inherited and acquired conditions that disrupt normal liver metabolism and function. This track covers disorders such as Wilson's disease, hereditary hemochromatosis, alpha-1 antitrypsin deficiency, glycogen storage diseases, and other rare genetic liver conditions. Discussions focus on molecular genetics, genomic medicine, diagnostic innovations, newborn screening, targeted therapies, and personalized treatment approaches that improve patient outcomes and long-term disease management.
Related Topics:
Metabolic Liver Disorders | Genetic Liver Diseases | Wilson's Disease | Hemochromatosis | Genomic Medicine | Rare Liver Diseases
Biliary Diseases
Biliary Diseases encompass a wide range of disorders affecting the bile ducts and gallbladder, including gallstones, cholangitis, biliary strictures, biliary tract cancers, and congenital biliary abnormalities. This session explores advances in diagnostic imaging, endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound (EUS), minimally invasive surgical techniques, and novel therapeutic interventions. Participants will discuss multidisciplinary approaches for improving diagnosis, treatment, and long-term management of biliary disorders.
Related Topics:
Biliary Diseases | Gallbladder Disorders | Cholangitis | ERCP | Endoscopic Ultrasound (EUS) | Hepatobiliary Diseases
Regenerative Medicine and Stem Cell Therapy
Regenerative Medicine and Stem Cell Therapy represent promising frontiers in the treatment of chronic liver diseases and liver failure. This track explores stem cell biology, liver regeneration, tissue engineering, bioartificial liver systems, gene editing technologies, and regenerative therapeutics. Discussions will focus on preclinical and clinical research, translational medicine, safety considerations, and innovative therapies aimed at restoring liver function and reducing the need for liver transplantation.
Related Topics:
Regenerative Medicine | Stem Cell Therapy | Liver Regeneration | Tissue Engineering | Cell Therapy | Translational Hepatology
Immunology and Liver Inflammation
Immunology and Liver Inflammation examine the complex immune mechanisms that contribute to acute and chronic liver diseases. This session explores innate and adaptive immune responses, inflammatory signaling pathways, cytokines, immune-mediated liver injury, autoimmune liver diseases, and liver fibrosis. Researchers and clinicians will discuss advances in immunotherapy, biomarker discovery, precision medicine, and novel anti-inflammatory treatments that are transforming the management of inflammatory liver disorders.
Related Topics:
Liver Immunology | Liver Inflammation | Immune-Mediated Liver Disease | Autoimmune Hepatitis | Immunotherapy in Hepatology | Inflammatory Liver Disorders
Market Analysis
Liver diseases remain a major global health challenge, with the increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis, alcohol-related liver disease, liver fibrosis, cirrhosis, and hepatocellular carcinoma driving significant demand for advanced diagnostics and innovative therapies. The global liver disease therapeutics market is projected to grow from approximately USD 18.5 billion in 2024 to USD 33.8 billion by 2032, at a CAGR of 7.8%, supported by advancements in precision medicine, biologics, gene therapies, and artificial intelligence. Increased investment in liver transplantation, regenerative medicine, non-invasive imaging technologies, and digital healthcare is further transforming hepatology. North America currently leads the market due to its strong research infrastructure, while Europe remains a hub for clinical innovation and international collaborations. The Asia-Pacific region is expected to witness the fastest growth owing to rising healthcare expenditure, improved disease awareness, and a growing patient population. As governments, academic institutions, pharmaceutical companies, and healthcare organizations continue to prioritize liver health, the 18th International Conference on Liver Diseases & Hepatology provides an ideal global platform for researchers, clinicians, industry experts, and policymakers to exchange knowledge, showcase emerging innovations, establish collaborations, and advance the future of hepatology and liver disease management.
Visa Support
We are committed to ensuring that your participation in Liver Diseases 2027 is as smooth and hassle-free as possible.
Our comprehensive visa support package includes:
-
Official Invitation Letter: An official invitation from the conference organizers confirming your participation. (The official invitation letter will be provided upon completion of your conference registration and payment.)
-
Abstract Acceptance Letter: Confirmation that your abstract has been accepted for presentation at the conference.
-
Payment Receipt: Proof of your conference registration and payment.
-
Visa Support Letter: A personalized letter outlining the purpose of your visit and the details of your stay in Paris. (The visa support letter will be provided upon completion of your conference registration and payment.)
These essential documents will be sent to you via email in PDF format to ensure quick and secure delivery.
We are dedicated to helping you navigate the visa application process efficiently, allowing you to focus on preparing for the conference. Should you have any questions or require additional assistance, please do not hesitate to contact us.
We look forward to welcoming you to Paris for a productive and enriching conference experience.
You may conveniently complete your payment through Payment Gateway/Stripe or via bank-to-bank transfer. For any inquiries or assistance regarding registration or invoices, please contact us at liverdiseases@speakersconclave.com.
To Collaborate Scientific Professionals around the World
Conference Date April 22-23, 2027
For Sponsors & Exhibitors
Speaker Opportunity
Useful Links
Past Conference Report
Supported By
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by